Lymphoma

1.4K

Pipeline Programs↗

585

Active Trials↗

319

Companies Involved↗

Lymphoma is a highly competitive landscape with 1432 programs across 319 companies. The most active players are Enzon Pharmaceuticals, Inc., Guangzhou Lupeng Pharmaceutical Company LTD., Taiho Oncology, Inc.. 69 therapies are approved with 147 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

89/100

Mech. Concentration

4/100

Completion Rate

74/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Enzon Pharmaceuticals, Inc.

4 programs

Guangzhou Lupeng Pharmaceutical Company LTD.

3 programs

Taiho Oncology, Inc.

3 programs

Alaunos Therapeutics

2 programs

Ono Pharmaceutical Co. Ltd

2 programs

Antengene Biologics Limited

2 programs

Pipeline

Programs by Phase

Preclinical77

Bleomycin Sulfate

Sequus Pharmaceuticals

Vinblastine Sulfate

Eastern Cooperative Oncology Group

Tafasitamab

Incyte

Pegaspargase

Servier

Rasburicase

Azienda U.S.L. 1 di Massa e Carrara

Phase 1505

Veliparib

AbbVie

Vemurafenib

Conrado Roberto Hoffmann Filho

Trastuzumab

Organon and Co

Tanespimycin

Bristol-Myers Squibb

Alefacept

Astellas

Phase 2634

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Isatuximab

Azienda U.S.L. 1 di Massa e Carrara

Cemiplimab

Regeneron

TAZEMETOSTAT

Epizyme, Inc.

Antineoplaston A10

Burzynski Research Institute

Phase 3147

Asparaginase

Dutch Childhood Oncology Group

Brentuximab Vedotin

Pfizer

Tocilizumab

Roche

Idelalisib

Gilead

Glofitamab

Roche

Approved69

Vinblastine

Eli Lilly

Exemestane

Pfizer

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Dacarbazine

Bayer

Abemaciclib

Eli Lilly

Analysis

Modality Breakdown

78%

Small molecule

1,216 of 1,566 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 1,566 classified programs, each share of the total. Modality classified for 100% of 1,775 pipeline programs.

Analysis

Trial Status

2,635

clinical trials

Completed1,189 · 45%

Unknown status430 · 16%

Recruiting345 · 13%

Terminated326 · 12%

Active, not recruiting147 · 6%

Withdrawn93 · 4%

Other105 · 4%

Clinical Trials

Trial Activity

2635 trials

A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1/2·NCT05623982·40 enrolled

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

Recruiting·—·Phase 2·NCT05833893·10 enrolled

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting·SSIRPant Immunotherapeutics, Inc.·Phase 1·NCT05967416·24 enrolled

Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

Recruiting·GGALIA AVRAHAMI·N/A·NCT02797717·2,200 enrolled

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Recruiting·SSecuraBio·Phase 3·NCT06522737·124 enrolled

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05355051·24 enrolled

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Recruiting·OOncoNano Medicine, Inc.·Phase 1·NCT06022029·168 enrolled

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Recruiting·IImmune Oncology Research Institute·Phase 2·NCT05891821·20 enrolled

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting·FFondazione Italiana Linfomi - ETS·N/A·NCT06008691·1,500 enrolled

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Recruiting·IIksuda Therapeutics Ltd.·Phase 1·NCT05365659·140 enrolled

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Recruiting· Takeda logo

Takeda·Phase 4·NCT06831370·124 enrolled

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06454968·45 enrolled

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Recruiting·NNational University of Malaysia·Phase 2·NCT06698484·20 enrolled

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Recruiting·KKK Women's and Children's Hospital·Phase 2·NCT05648019·40 enrolled

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06464861·52 enrolled

Page 1 of 176

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)